Articles related to STIMULANTS

Recent research indicates an incremental risk of cardiomyopathy associated with extended stimulant use in ADHD treatment among young adults. Notably, this risk peaks at eight years of therapy, reinforcing the need for vigilant cardiovascular monitoring.

Caffeine’s impact on medication efficacy is significant, with interactions that can enhance or reduce drug effects. Notably, it can increase the risk of cardiovascular side effects when combined with drugs like Sudafed and elevate blood levels of certain antipsychotics.

This study offers valuable insights into the safety of stimulant medication use during pregnancy, highlighting the need for nuanced patient counseling and consideration of individual risks and benefits in managing ADHD symptoms.

The study suggests that although unlicensed doses may lead to additional symptom reduction, the gains are small and come with an increased risk of adverse events.

A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.

Discover how viloxazine ER could offer a new avenue for enhancing ADHD treatment efficacy in pediatric patients with inadequate response to stimulants.